PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.\', \'Department of Safety Assessment, Genentech, Inc., South San Francisco, California, USA.\', \'Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.\', \'PDMA-Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1002/jcph.1855
?:hasPublicationType
?:journal
  • Journal of clinical pharmacology
is ?:pmid of
?:pmid
?:pmid
  • 33719071
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.997
?:rankingScore_hIndex
  • 104
is ?:relation_isRelatedTo_publication of
?:title
  • Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33719071>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33719071>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all